Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gossamer Bio Inc (NQ: GOSS )

1.250 +0.070 (+5.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,316,264
Open 1.190
Bid (Size) 1.250 (25)
Ask (Size) 1.290 (9)
Prev. Close 1.180
Today's Range 1.185 - 1.330
52wk Range 0.4525 - 1.880
Shares Outstanding 75,993,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets. 
Via Benzinga
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga

Performance

YTD
+28.87%
+28.87%
1 Month
+140.34%
+140.34%
3 Month
+52.29%
+52.29%
6 Month
+33.96%
+33.96%
1 Year
-18.30%
-18.30%

More News

Read More
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
Via InvestorPlace
HC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024
Via InvestorPlace
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
Via Benzinga
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
Via Benzinga
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
Via InvestorPlace
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Via InvestorPlace
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.